Ceribell, Inc. ( (CBLL) ) has released its Q3 earnings. Here is a breakdown of the information Ceribell, Inc. presented to its investors.

SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with ...

While the artificial intelligence (AI) megatrend has captured the imagination of global investors, the rally so far has been ...

SUNNYVALE, Calif., Oct. 15, 2024 /PRNewswire/ -- CeriBell, Inc. (Nasdaq: CBLL) ("Ceribell"), a commercial-stage medical technology company focused on transforming the ...

Shares of CeriBell (NASDAQ:CBLL) have seen a very successful public offering, as shares have risen some sixty percent from the official public offering price. The company has developed and ...

Canaccord initiated coverage of Ceribell (CBLL) with a Buy rating and $30 price target The firm views Ceribell as the pioneer and leader in rapid EEG. It estimates the company is initially ...

Ceribell, Inc. is a commercial-stage medical technology company, which focuses on transforming the diagnosis and management of patients with serious neurological conditions. Its products include Point ...

As previously reported, BofA analyst Travis Steed initiated coverage of Ceribell (CBLL) with a Buy rating and $32 price target The company has a first-mover advantage with its rapid point of care ...